SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
June 05, 2023 06:30 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., June 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
May 30, 2023 06:30 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., May 30, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients...
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
May 25, 2023 17:05 ET
|
SpringWorks Therapeutics, Inc.
- Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using Multiple Assessment Tools - - Substantial Reductions in MRI-Assessed Tumor Volume...
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
May 24, 2023 07:00 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients...
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
May 11, 2023 12:14 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients...
SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 03, 2023 06:30 ET
|
SpringWorks Therapeutics, Inc.
– NDA for Nirogacestat in Adults with Desmoid Tumors Accepted by the FDA and Granted Priority Review; PDUFA Action Date Set for August 27, 2023 – – Phase 3 DeFi Trial Evaluating Nirogacestat in...
SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
May 02, 2023 07:00 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients...
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023 14:32 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX:...
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023 14:30 ET
|
SpringWorks Therapeutics, Inc.
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass. and SAN MATEO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- MapKure, LLC, SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), and...
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors
March 08, 2023 17:05 ET
|
SpringWorks Therapeutics, Inc.
– Nirogacestat Treatment Significantly Improved Progression-Free Survival, Objective Response Rate and Key Patient Reported Outcomes – – New Drug Application Under Review by the FDA...